Identify Prognostic Biomarkers of Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers for Diagnosis of Lung Cancer

NCT02050100

Lung Cancer Lung Neoplasm

COMPLETED

Multiomics Tumor Evolution Model of NSCLC

NCT05352035

Non-small Cell Lung Cancer

RECRUITING

Multiplex Analysis of Circulating Tumor DNA

NCT03301961

Carcinoma Non-small-cell Lung Cancer Lung Neoplasm

UNKNOWN

Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China

NCT01928836

Lung Neoplasms

COMPLETED

Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach（Radiogenomics-Lung）

NCT06500312

Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung cancer is the leading cause of cancer-related death in China. In order to improve prognosis of lung cancer as well as provide new therapeutic targets, the identification of effective biomarkers for the prognosis of lung cancer is of great significance. It has been reported that some small molecules such as lncRNA, circRNA and polypeptides in human plasm have good prospects in diagnosing or evaluating the stage of diseases. In this study, we planned to use multi-omics combined with clinical data to discovery some small molecules that are potential to predict the prognosis of lung cancer patients. In addition, we want to construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. And we hope our study can provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy control

healthy people

No interventions assigned to this group

lung cancer

patients diagnosed with lung cancer

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with lung cancer;
* Untreated lung cancer patients;
* No history of chronic or serious diseases, such as cardiovascular disease, liver disease, kidney disease, respiratory disease, blood disease, lymphatic disease, endocrine disease, immune disease, mental disease, neuromuscular disease, gastrointestinal system disease, etc.

Exclusion Criteria

* Patients with other tumors;
* Lung cancer patients who had been treated;
* Abnormal liver and kidney function;
* Acute and chronic infectious diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes